by MM360 Staff | Jun 5, 2025 | Uncategorized
Source: CureToday articles I reflect on finding peace, purpose and presence after my diagnosis through a creative writing exercise rooted in mindfulness and metaphor. Read More
by MM360 Staff | Jun 5, 2025 | Uncategorized
Source: CureToday articles Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Read More
by MM360 Staff | Jun 5, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | Jun 5, 2025 | Myeloma News
Source: Pharmacy Times articles Vincent Chung, MD, discusses key findings from the NAPOLI-3 trial and offers guidance for pharmacists on managing toxicities, adjusting dosing, and supporting patients receiving NALIRIFOX for metastatic pancreatic ductal adenocarcinoma....
by MM360 Staff | Jun 5, 2025 | Uncategorized
Source: CureToday articles Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials. Read More